Neurocrine Biosciences, Inc.’s filing revealed that its Chief Regulatory Officer Delaet Ingrid unloaded Company’s shares for reported $37346.0 on Apr 01 ’24. In the deal valued at $137.30 per share,272 shares were sold. As a result of this transaction, Delaet Ingrid now holds 7,507 shares worth roughly $1.05 million.
Then, Delaet Ingrid sold 5,000 shares, generating $725,320 in total proceeds. Upon selling the shares at $145.06, the Chief Regulatory Officer now owns 7,507 shares.
Before that, BENEVICH ERIC sold 75,000 shares. Neurocrine Biosciences, Inc. shares valued at $10,453,417 were divested by the Chief Commercial Officer at a price of $139.38 per share. As a result of the transaction, BENEVICH ERIC now holds 40,778 shares, worth roughly $5.69 million.
A number of analysts have revised their coverage, including Deutsche Bank’s analysts, who began to cover the stock in mid December with a ‘”a Buy”‘ rating. Mizuho maintained its rating on August 21, 2023. It rated NBIX as “a Neutral”.
Price Performance Review of NBIX
On Monday, Neurocrine Biosciences, Inc. [NASDAQ:NBIX] saw its stock jump 0.37% to $139.44. Over the last five days, the stock has lost -1.37%. Neurocrine Biosciences, Inc. shares have risen nearly 5.83% since the year began. Nevertheless, the stocks have risen 36.43% over the past one year. While a 52-week high of $148.37 was reached on 03/21/24, a 52-week low of $89.04 was recorded on 02/07/24. SMA at 50 days reached $137.30, while 200 days put it at $118.59. A total of 0.62 million shares were traded, compared to the trading of 0.61 million shares in the previous session.
Levels Of Support And Resistance For NBIX Stock
The 24-hour chart illustrates a support level at 138.21, which if violated will result in even more drops to 136.99. On the upside, there is a resistance level at 140.17. A further resistance level may holdings at 140.91. The Relative Strength Index (RSI) on the 14-day chart is 52.92, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.10, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 59.75%. Stochastics %K at 35.01% indicates the stock is a holding.
How much short interest is there in Neurocrine Biosciences, Inc.?
A steep rise in short interest was recorded in Neurocrine Biosciences, Inc. stocks on Mar 15, 2024, growing by 0.3 million shares to a total of 2.48 million shares. Yahoo Finance data shows the prior-month short interest on Feb 15, 2024 was 2.18 million shares. There was a rise of 12.1%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 2.90% of the overall stock float, the days-to-cover ratio (short ratio) rose to 2.72.
